ABSTRACT: Aflatoxins (AFs) and fumonisins (FBs) can co-contaminate foodstuffs and have been associated with hepatocellular and esophageal carcinomas in humans at high risk for exposure. One strategy to reduce exposure (and toxicity) from contaminated foodstuffs is the dietary inclusion of a montmorillonite clay (UPSN) that binds AFs and FBs in the gastrointestinal tract. In this study, the binding capacity of UPSN was evaluated for AFB 1 , FB 1 and a combination thereof in Fischer 344 rats. Rats were pre-treated with different dietary levels of UPSN (0.25% or 2%) for 1 week. Rats were gavaged with a single dose of either 0.125 mg AFB 1 or 25 mg FB 1 per kg body weight and a combination thereof in the presence and absence of an aqueous solution of UPSN. The kinetics of mycotoxin excretion were monitored by analyzing serum AFB 1 -albumin, urinary AF (AFM1) and FB 1 biomarkers over a period of 72 h. UPSN decreased AFM1 excretion by 88-97%, indicating highly effective binding. FB 1 excretion was reduced, to a lesser extent, ranging from 45% to 85%. When in combination, both AFB 1 and FB 1 binding occurred, but capacity was decreased by almost half. In the absence of UPSN, the combined AFB 1 and FB 1 treatment decreased the urinary biomarkers by 67% and 45% respectively, but increased levels of AFB 1 -albumin, presumably by modulating its cytochrome metabolism. UPSN significantly reduced bioavailability of both AFB 1 and FB 1 when in combination; suggesting that it can be utilized to reduce levels below their respective thresholds for affecting adverse biological effects.
INTRODUCTION
Naturally occurring foodborne carcinogens, such as aflatoxins and fumonisins, are predominantly investigated as independent compounds. However, complex mixtures of mycotoxins occur in the environment and could induce additive, antagonistic, or synergistic interactions when present together (Carpenter et al., 1998) . Previous research has demonstrated that multiple mycotoxins can co-contaminate crops and foods intended for both animal and human consumption (Kimanya et al., 2008; Sun et al., 2011; Almeida et al., 2012) . Concomitant exposure to mycotoxins, such as aflatoxin and fumonisin, has been associated with various teratogenic, mutagenic, estrogenic, neurogenic and immunotoxic effects, as well as growth faltering, cancer, and even death in acute incidences (Wogan, 1992; IARC, 1993 IARC, , 2002 Coulumbe, 1994; Gong et al., 2002 Gong et al., , 2004 Williams et al., 2004; Azziz-Baumgartner et al., 2005; Wild and Gong, 2010) . In particular, foods intended for human consumption in Sub-Saharan Africa have been shown to contain high levels of both aflatoxins and fumonisins (Kpodo et al., 2000; Kimanya et al., 2008) . Although research investigating the health effects owing to co-exposure of these two mycotoxins is limited, several previous studies have elucidated their additive and synergistic capability. Co-exposure has been shown to increase toxicity in a hydra model (Brown et al., 2012) , alter toxic responses in rats and mosquito fish (McKean et al., 2006) , lower feed conversion and mean body weight in pigs (Dilkin et al., 2003) , and increase the development of hepatocyte nodules in a rodent model (Gelderblom et al., 2002) .
Aspergillus flavus and A. parasiticus fungi naturally produce four congeners of aflatoxins: AFB 1 , AFB 2 , AFG 1 , and AFG 2 . AFB 1 (Fig. 1A) is the most potent carcinogen of the four and is also the most commonly occurring in maize and groundnut crops (CAST, 2003) . The International Agency for Research on Cancer (IARC) has classified AFB 1 as a Group 1A carcinogen, due to its ability to induce liver cancer in humans. Consumption of contaminated foods has been implicated as the primary route of AFB 1 exposure, resulting in an increased risk for the development of hepatocellular carcinoma (Ross et al., 1992; Qian et al., 1994; Wang et al., 1996; Yu et al., 1997) and hepatic failure resulting in death (Lewis et al., 2005) . Exposure to AFB 1 occurs predominantly in tropical and subtropical regions (including the US) that lie between the latitudes of 40°N and 40°S, where the climate promotes growth of the Aspergillus fungi and production of aflatoxins. These regions include Sub-Saharan Africa and Southeast Asia; where liver cancer is most prominent.
Fumonisin B1 (Fig. 1B ) is a congener of the fumonisin toxins produced by Fusarium verticillioides and F. proliferatum fungi and is the most abundantly produced fumonisin as well as the most toxicologically significant. FB 1 , like AFB 1 , is a common contaminant of maize and has been found in high levels in Sub-Saharan Africa, Central America, and Southeast Asia. Exposure to FB 1 has been implicated in various disease outcomes, illustrating the diverse biological effects that this toxin is capable of eliciting. Fumonisin has been linked to esophageal cancer, liver tumors, immune stimulation and suppression, neural-tube defects, nephrotoxicity, and other abnormalities (Chu and Li, 1994; Voss et al., 2002; Marasas et al., 2004; Grenier et al., 2011) . A recent study indicated that FB 1 is also associated with stunting in infants (Kimanya et al., 2010) . FB 1 exhibits hepatoand nephrocarcinogenic effects in rats and is classified as a Group 2B carcinogen, i.e. possibly carcinogenic to humans (IARC 1993 (IARC , 2002 . FB 1 is mainly regarded as a liver cancer promoter (Gelderblom et al., 1988) , and has been shown to have synergistic interactions with AFB 1 in two-stage cancer initiation/promotion liver models utilizing rainbow trout and rats Gelderblom et al., 2002) .
As AFB 1 and FB 1 commonly co-contaminate foods, any therapeutic approach that could mitigate both mycotoxins would be highly attractive and more cost-effective than a combination of approaches. In particular, populations most at risk for exposure to both mycotoxins also suffer from food insecurity and poor economic conditions. Thus, a remediation strategy for such communities must function to reclaim contaminated foods in their entirety and cause minimal interference to daily life. In this study, a refined calcium montmorillonite clay, uniform particle size NovaSil (UPSN), was investigated for its potential to simultaneously and adequately absorb both toxins in vivo. UPSN is from the family of smectites that has been shown to absorb AFB 1 in vitro and in numerous animal and human models, thereby decreasing biomarkers of exposure in the urine and blood and protecting animals from toxic endpoints (Phillips et al., 1988; Colvin et al., 1989; Beaver et al., 1990; Edrington et al., 1996; Pimpukdee et al., 2004) . Recently, in vitro analyzes indicated that UPSN efficaciously bound FB 1 as well as mixtures of AFB 1 and FB 1 (Brown et al., 2012) . This same study found that 1.4% UPSN adequately protected Hydra vulgaris organisms from AFB 1 and FB 1 co-exposure.
In the present study, our objectives were (i) to determine whether a dual protection would be feasible in a mammalian gastrointestinal system and (ii) to assess the difference in UPSN efficacy when a mixture of AFB 1 and FB 1 is present, as opposed to a single toxin exposure. To investigate the effect that UPSN would have on AFB 1 and FB 1 bioavailability, well-established biomarkers of exposure to both toxins, i.e. urinary AFM1, FB 1 and serum AFB 1 -albumin adducts were utilized (Gan et al., 1988; Groopman et al., 1994; Cai et al., 2007; Shephard et al., 2007) . Levels of each biomarker were analyzed after exposure to a single treatment of AFB 1 , FB 1 , or a combination of both toxins with and without UPSN treatment.
Materials and Methods

Reagents
High-performance liquid chromatography (HPLC) grade methanol and acetonitrile, as well as reagent grade hydrochloric acid, formic acid, sodium phosphate monobasic, sodium borate, sodium cyanide, dibasic potassium phosphate and pH buffers (4.0, 7.0, and 10.0) were purchased from VWR (Atlanta, GA, USA). O-phthaldialdehyde (OPA), AFM1, and FB 1 analytical standards were purchased from Sigma-Aldrich (Saint Louis, MO, USA). FB 1 specified for animal treatment was purchased from the PROMEC Unit of the South African Medical Research Council (Tygerbreg, South Africa). UPSN was obtained from Texas Enterosorbents (Bastrop, TX, USA). Ultrapure deionized water (18.2 MΩ) was used in all experiments.
Animal Housing, Diet and Treatments
Five-week old male Fischer 344 rats were purchased from Harlan (Houston, TX, USA) and allowed to acclimate for 1 week before being randomly divided into 10 treatment groups consisting of six animals per group (Table 1) . Briefly, the treatment groups included an absolute control, positive controls (dosed with AFB 1 , FB 1 , or a mixture of the two) and groups treated with a one-time toxin dose in addition to UPSN clay (0.25% or 2% w/w feed consumption). These concentrations were chosen based on previous single toxin animal and human studies completed by our laboratory, in which 0.25% and 2% significantly reduced aflatoxin and fumonisin biomarkers, respectively (Phillips et al., 2002; Pimpukdee et al., 2004; Robinson et al., 2012) . Control animals (no UPSN) were maintained on a nutritionally complete powdered feed (Teklad rodent diet 8604, Harlan) and water ad libitum. Animals that were placed in the 0.25% or 2% UPSN treatment groups received Teklad 8604 powdered feed homogenously mixed with UPSN at the Robinson et al., 2012) . Aqueous gavage solutions administered to UPSN treatment groups also contained UPSN at an amount equivalent to one day's intake. UPSN and toxins were mixed immediately before the gavage procedure to simulate the addition of UPSN to mycotoxincontaminated foods just prior to human consumption. Based on an average daily feed consumption of 20 g the doses were as follows: the 0.25% group was gavaged with 0.05 g and the 2% groups were given 0.4 g UPSN, respectively. After gavage, animals were housed individually in metabolic cages (Nalgene TM ) for 72 h and urine was collected at 12, 24, 36, 48, and 72 h. Samples were stored at À20°C for AFM1 and FB 1 biomarker analyses. Animals were anesthetized via isofluorane gas administration 72 h after gavage and then blood samples were collected via a heart stick. Euthanasia was accomplished by exsanguination. Serum samples were stored at À20°C until AFB 1 -albumin analysis. Liver and kidney weights were also recorded and expressed as a percentage of the total body weight.
Analysis of Urinary AFM1
AFM1 concentrations in the urine were analyzed using immunoaffinity column purification using methods previously described Sarr et al., 1995; Wang et al., 1999) . Each urine sample (1 ml) was adjusted to an acidic pH with 1.0 M ammonium formate (pH 4.5) and the volume increased to 10 ml with water. Samples were then passed through a VICAM TM AflaTest WB immunoaffinity column (VICAM, Watertown, MA, USA) at a rate of 1 ml per min. After two separate washing steps, AFM1 was eluted with 2 ml of 80% methanol. Samples were dried under nitrogen gas and re-constituted with 100 μl of 20 mM ammonium formate and 100 μl of 80% methanol. A Waters HPLC system (Waters Corporation, Milford, MA, USA) with fluorescence detection (excitation 365 nm and emission 425 nm) was used to separate sample constituents and isolate the AFM1 metabolite. Chromatographic separation was achieved by isocratic elution of the mobile phase (22% ethanol: 78% 20 mM ammonium formate in water) on a 250 × 4.6 mm LiCrospher RP-18 end-capped column with pore size 100 Å and 5 μm particle size (Discovery Sciences, Deerfield, IL, USA). Quantification of AFM1 was based on peak area and retention time as compared with external standards run between every five samples. The limit of detection for urinary AFM1 using this method was 4.8 pg. Creatinine analysis was performed on all urine samples at the Texas Veterinary Medical Diagnostic Laboratory (College Station, TX, USA) to adjust for variations in urine dilution.
Analysis of Urinary FB 1
After centrifugation, a 300 μl aliquot of supernatant was loaded into a pre-equilibrated VICAM TM FumoniTest immunoaffinity column and passed through by gravity. After washing with 10 ml of PBS, FB 1 was eluted three times with 0.5 ml of 20% methanol in 10 mM hydrochloric acid directly onto a pre-conditioned Waters Oasis HLB cartridge (3 cc, 60 mg, 30-μm particle size). The HLB cartridge was sequentially washed with 2 ml of water and 2 ml of 30% aqueous methanol, and then eluted three times with 0.6 ml of 2% formic acid in methanol. Eluents were evaporated to dryness under nitrogen gas while incubated at 35°C. Dry residues were reconstituted with 150 μl of 50% aqueous methanol. HPLC-fluorescence analysis was carried out on an Agilent 1100 liquid chromatography system (Agilent Technologies, Santa Clara, CA, USA). FB 1 molecules were derivatized with o-phthaldialdehyde (OPA) prior to fluorescence detection (Xu et al., 2010) . To avoid degradation of the derivatives, an on-line automatic injector thoroughly mixed 20 μl of OPA reagent with the sample for 1 min immediately prior to each injection. Chromatographic separations were performed on a Luna C18 (2) column (Phenomenex Torrance, CA, USA; 5 μm particle size, 250 × 4.6 mm), maintained at 35°C. Molecules were resolved with a linear gradient starting from 0.1 M sodium phosphate monobasic (pH 3.4): methanol (35/65, v/v) to 0.1 M sodium phosphate monobasic (pH 3.4): methanol (20/80, v/v) over 13 min, with a flow rate of 1.0 ml per min and an injection volume of 100 μl. The OPA derivative was monitored at an emission wavelength of 440 nm and excitation wavelength of 330 nm. The limit of detection for this method was 20 pg.
Analysis of Serum AFB 1 -Albumin Adduct
Serum from all AFB 1 and AFB 1 /FB 1 treatment animals was assessed for AFB 1 -albumin levels 72 h after gavage. The methodology to complete this analysis was adopted as previously reported (Qian et al., 2010 (Qian et al., , 2013 . Briefly, 150 μl of serum was digested with pronase (pronase:total protein, 1:4, w/w) for 3 h at 37°C. The digest was further purified by a solid phase cartridge, evaporated, reconstituted, and injected into an Agilent 1200 HPLC system for quantification by fluorescence signal. Excitation and emission wavelengths were 405 and 470 nm, respectively. The limit of detection was 0.4 pg mg -1 albumin.
Serum AFB 1 -albumin adduct concentrations were adjusted by total serum albumin content.
Statistical Analysis
Serum levels of AFB 1 -albumin adduct and urinary AFM1 and FB 1 are expressed as mean ± standard deviation (SD). Data was not normally distributed and was therefore log transformed for statistical analysis. Comparisons of these parameters between treated groups and the control group were conducted using one-way analysis of variance (ANOVA) followed by a Dunnett's test to compare each UPSN group with it's respective positive control. Differences between the UPSN-treated groups were analyzed via a Tukey's test. A P-value of less than 0.05 was considered statistically significant.
Results
Organ and Body Weights
No significant differences in body weight, body weight gain, or target organ weights were observed during the study. At the conclusion of the experiment (72 h), animals weighed 145.3 ± 14.5 g. Table 2 shows the somatic index for each organ by treatment group.
Montmorillonite clay reduces AFB 1 & FB 1 biomarkers
AFM1 Analysis from AFB 1 -Treated Groups
The mean urinary AFM1 was calculated based on six rats per treatment group. Absolute control animals receiving an equal volume (0.75 ml) gavage of ultra-pure water did not have detectable AFM1 metabolites in the urine at any of the collection time points. Excretion of AFM1 peaked between 12 and 24 h after AFB 1 treatment. Five out of six rats were completely void of AFM1 by the 36-h timepoint (Fig. 2A) . The positive control group displayed the highest average concentration of AFM1 (201 ng mg -1 creatinine) at the 12-h time point. Comparisons of AFM1 levels between UPSN treatment groups and positive controls showed a marked decrease in overall excretion of AFM1 metabolites. UPSN treatment reduced AFM1 biomarkers in a dose-dependent manner with the largest reduction observed in the 2% treatment group. UPSN at 0.25% reduced AFM1 excretion by 88%, 94%, and 85% at 12, 24, and 36-h time points, respectively (Fig. 2B) . AFM1 levels in the 2% UPSN treatment group were reduced by 97%, 99%, and 58% at 12, 24, and 36 h, respectively. The decrease in AFM1 observed in both of the UPSN treatment groups was highly significant (P < 0.001) at 12 and 24 h from the positive controls. The 0.25% UPSN group was also significantly different from the 2% UPSN group (P = 0.0215).
AFM1 Levels in AFB 1 /FB 1 Treatment Groups AFM1 excretion patterns were different between AFB 1 treatment groups and AFB 1 /FB 1 mixture groups. AFM1 excretion by the coexposure group peaked at 12 h and was almost undetectable by 24 h. The highest average AFM1 concentration in the urine was 118 ng mg -1 creatinine at 12 h in animals dosed with the AFB 1 / FB 1 mixture (Fig. 2C ). This value is approximately two times lower than the average concentration in animals dosed with AFB 1 alone. There was considerable variation observed in the overall excretion of AFM1 in the AFB 1 /FB 1 -treated positive control group (SD of 117,002). Therefore, although the average AFM1 output at 12 h was almost two times higher for the AFB 1 -treated group alone the two groups were not significantly different from each other. UPSN treatment dose-dependently reduced AFM1 excretion in animals exposed to the AFB 1 /FB 1 mixture. However, the percent reductions observed in the mixture groups were lower than those in the AFB 1 control groups. Compared with the AFB 1 /FB 1 positive controls, the 0.25% UPSN group exhibited AFM1 decreases of 66% and 32% at 12 and 24 h, respectively. AFM1 levels were non-detectable in any groups treated with UPSN by the 36-h timepoint. AFM1 excretion levels observed during UPSN inclusion were significantly different from the AFB 1 /FB 1 control group for the 2% UPSN only at the 12-h time point (P = 0.0039). The 0.25% UPSN group excreted levels significantly higher than the 2% UPSN group (P = 0.0286) at 12 h. AFM1 excretion in the 0.25% UPSN group was not significant at this time point most probably as a result of the high standard deviation observed in the AFB 1 /FB 1 control group. Although the UPSN-treated groups had a lower AFM1 output at 24 h than the control group, the difference was not statistically significant.
FB 1 Analysis from FB 1 Treated Animals
Urine samples were also analyzed for FB 1 with HPLC-coupled fluorescence detection. The mean FB 1 levels were calculated from six animals per treatment group. Absolute control animals did not have detectable levels of FB 1 present in their urine at any time point assessed. As expected, the highest levels of FB 1 excretion occurred 12 h post-gavage and decreased rapidly (Fig. 3A) . At 12 h, the mean urinary excretion for animals dosed with FB 1 alone was 737 ± 110 ng mg -1 creatinine. The addition of UPSN clay at the 2% w/w level significantly decreased the amount of FB 1 excreted at 12, 24, and 36 h compared with the positive control group (P < 0.0001). The 2% UPSN group also excreted significantly lower FB 1 than the 0.25% UPSN group at the 12, 24, and 36-h time points (P = 0.0013, P 0.0001 and P = 0.0127, respectively). However, the 0.25% UPSN group was not significantly different from the positive control group at any of the time points except 36 and 72 h (P = 0.0141 and 0.0284, respectively). Although not significant at 12 and 24 h, 0.25% UPSN decreased overall excretion of FB 1 as well. The mean levels of FB 1 excreted by the 0.25% and 2% UPSN groups at 12 h were 407 ± 168 and 109 ± 136 ng mg -1 creatinine, respectively, and 258 ± 139 and 12 ± 7 ng mg -1 creatinine at 24 h. The overall reduction of the FB 1 biomarker for the 0.25% UPSN inclusion group was 45% at 12 h and 55% at 24 h, compared with the positive control group. UPSN inclusion at the 2% level reduced urinary FB 1 by 85% and 98% at 12 and 24 h (Fig. 3B) .
FB 1 Analysis from AFB 1 /FB 1 Co-Treatment
The mean urinary levels of FB 1 were 572 ± 260 and 94 ± 62 ng mg
creatinine at 12 and 24 h post-gavage, respectively, in the AFB 1 /FB 1 co-treated positive control samples. A dose-dependent reduction in urinary FB 1 was observed for the UPSN-treated AFB 1 /FB 1 groups, with the 2% UPSN group exhibiting the largest difference from the positive control group (Fig. 3C) . The FB 1 biomarker in the 0.25% UPSN group was reduced by 28% and 39% at 12 and 24 h after gavage and by 51% and 59% for the 2% UPSN group, respectively (Fig. 3D) . A reduction in FB 1 was significant in the 2% UPSN group at 12 (P = 0.0177), 24 (P = 0.0284), and 72 h (P < 0.0001) time points compared to the positive controls. The reduction observed in the 0.25% UPSN group was not statistically significant except at the 72-h time point (P = 0.0369). Figure 4 shows the differences in kinetics for total AFM1 and FB 1 excretion in the urine by calculations of area under the curve (AUC) for each treatment group. Based on AUC, approximatley 75% of the total AFM1 excreted was detected within the first 24 h after AFB 1 exposure in the positive control group. The 0.25% UPSN group excreted the equivalent of 9% of the total AFM1 that was excreted by the AFB 1 -treated positive control group (Fig. 4A) . Based on the total AUC, the 2% UPSN group excreted the equivalent of 2% of the amount of AFM1 excreted by the AFB 1 -treated positive control, respectively. The mean excretion of AFM1 biomarkers was significantly different (P = 0.0002) between animals dosed with AFB 1 alone and animals receiving both AFB 1 and FB 1 . The AUC value for AFM1 excretion in the AFB 1 /FB 1 control animals was approximately three times smaller than the AUC for the AFB 1 control animals (Fig. 4A ). Based on AUC values, the 0.25% and 2% UPSN groups excreted the equivalent of 37% and 7% of the AFM1 excreted by the AFB 1 /FB 1 positive controls. Approximately 71% of the total FB 1 excreted by the FB 1 -treated positive control group was excreted within the first 24 h after gavage. Based on the AUC calculations, the 0.25% UPSN group excreted the equivalent of 52% of the total FB 1 excreted by the FB 1 -treated control group. The 2% UPSN group excreted the equivalent of 16% of the total FB 1 excreted by the FB 1 -treated control group (Fig. 4B) . Similar to the change in kinetics of AFM1 excretion after AFB 1 /FB 1 co-exposure, total FB 1 excreted in AFB 1 /FB 1 combination groups was significantly lower than total FB 1 excreted in the FB 1 -treated controls (P = 0.0377). The total AUC values indicated a 45% reduction in the amount of FB 1 excreted by the AFB 1 /FB 1 combination group compared with the positive control group. Based on the AUC calculations, the 0.25% and 2% UPSN groups excreted the equivalent of 64% and 43% of the total FB 1 excreted by the AFB 1 /FB 1 positive controls (Fig. 4B) . UPSN treatment was less effective in reducing AFM1 and FB 1 urinary biomarkers after AFB 1 /FB 1 co-exposures than after exposure to either AFB 1 or FB 1 alone.
Area Under the Curve Calculations
AFB 1 -Albumin Analysis
Analysis of AFB 1 -albumin adducts in the serum was conducted after euthanasia (72 h after gavage). Means and standard deviations were calculated based on six animals per group. Compared with positive control groups, both UPSN concentrations significantly reduced AFB 1 -albumin adduct levels (all P-values < 0.0001). A UPSN concentration of 0.25% was also significantly different (P < 0.0001) compared with the 2% group (Fig. 5A) . The mean AFB 1 -albumin concentration was 632 pg mg -1 albumin for the positive control group (AFB 1 treatment alone), whereas serum from the 0.25% and 2% UPSN groups contained 101 and 36 pg mg -1 albumin, respectively. The percent reduction in AFB 1 -albumin levels by UPSN treatment group are shown in Fig. 5B . Animals that were gavaged with a combination of AFB 1 /FB 1 had significantly higher AFB 1 -albumin levels (P = 0.0061) than the AFB 1 -treated controls. However, UPSN clay was still capable of significanlty decreasing the AFB 1 -albumin biomarker in a dose-dependent manner (Fig. 5A ). In the AFB 1 /FB 1 combination group, the mean AFB 1 -albumin level was 1,112 pg mg -1 albumin.The adduct concentrations in the 0.25%
and 2% UPSN groups co-exposed to AFB 1 /FB 1 were significantly different from each other (242 and 37 pg mg -1 albumin, respectively).
Discussion
Previous isothermal data from our laboratory indicated that NovaSil clay (a calcium montmorillonite) can tightly absorb AFB 1 and reduce the bioavailability of AFB 1 in the gastrointestinal tract of animals and humans . Importantly, clay treatment resulted in lower levels of well-established shortand long-term biomarkers of aflatoxin exposure in the urine and serum, i.e. AFM1 and AFB 1 -albumin adducts . Recent studies demonstrated that NovaSil clay also reduced biomarker levels of FB 1 in rats and humans (Robinson et al., 2012). A uniform particle size NovaSil clay (UPSN) was produced to maintain purity and consistency from batch to batch for use in human populations. In preliminary work, UPSN was shown to retain the binding properties of the parent product (NovaSil) (Marroquin-Cardona et al., 2011) . Binding analysis performed with heat-collapsed UPSN suggests that AFB 1 and FB 1 binding is saturable and occurs largely within the interlayer regions of the clay (Grant and Phillips, 1998; Brown et al., 2012) providing preliminary evidence that both mycotoxins may compete for the same binding sites on surfaces of UPSN. In the present study, inclusion of UPSN montmorillonite clay during aflatoxin exposure decreased the excretion of AFM1 in the urine and the production of the AFB 1 -albumin adduct in the serum of rats. The overall excretion of AFM1 was similar to that reported in a study utilizing Fischer 344 rats in which the majority of AFM1 excreted in the urine occurred within the first 12 h after gavage of AFB 1 . A study utilizing dogs demonstrated that calcium montmorillonite treatment, via food inclusion, after AFB 1 gavage could lower urinary excretion of AFM1 by as much as 65% (Bingham et al., 2004) . Species differences in absorption, metabolism, length of digestion, clay dose dissemination, and treatment regimen could all possibly account for the differences in efficacy seen between these studies. While dogs will consume an entirety of a meal in one sitting, this is not typically the case in rodents. Thus, it was deemed necessary to include UPSN in the gavage solution for the rodent model to ensure adequate opportunity for UPSN to interact with AFB 1 , thereby preventing adsorption into the vascular system. The difference in binding efficacy obtained in the present study could be ascribed to the route of exposure (i.e. gavage vs. dietary) and other physiological conditions prevailing in the gut of rodents.
Although extensive research focusing on the binding capacity of calcium montmorillonite for aflatoxin has been conducted, it is only recently that its sorption capability for fumonisin has been addressed. Robinson et al. (2012) demonstrated a significant decrease in fumonisin biomarkers of exposure after treatment with clay in both rats and humans. In the rodent model given 2% clay, FB 1 excretion in the urine was reduced by 20% at 24 h post-gavage and 50% at 48 h post-gavage (Robinson et al., 2012) . In the present study, the reduction of FB 1 biomarkers after inclusion of 2% UPSN was higher (97%) after 24 h. The protocols for these two studies were similar; however, in this study a refined form of calcium montmorillonite (UPSN) was used with a narrower range of particle size (45-100 μm) compared with the parent clay utilized in the Robinson et al. (2012) study. This difference could influence binding affinity and the reduction of urinary metabolites. Isothermal analysis has yet to be conducted to verify this hypothesis, therefore binding affinity could still be considered a factor in the increased reduction of urinary metabolites.
The present study verifies the results reported for other rodentbased metabolic studies indicating that treatment with UPSN can reduce the excretion of AFM1 and FB 1 in the urine after exposure to the mycotoxins separately. However, AFB 1 and FB 1 can co-occur under natural conditions (Kimanya et al., 2008; Sun et al., 2011; Almeida et al., 2012) which could enhance the risk owing to possible synergistic and/or additive effects. The mixture of AFB 1 and FB 1 resulted in a slightly lowered efficacy of UPSN in reducing these mycotoxins. Based on AUC calculations, the 2% UPSN group reduced the total amount of AFM1 excreted by 98% in the AFB 1 -treated group alone, and 93% in the AFB 1 /FB 1 -treated group. AUC values indicated that 2% UPSN decreased total fumonisin excretion by 84% in the FB 1 -treated group and only reduced by 57% in the AFB 1 / FB 1 mixture. The reduced efficacy of UPSN binding observed in the mixture groups could be an indicator of competition for binding sites on the clay. It is evident from this data that although UPSN can bind both AFB 1 and FB 1 , it will preferentially bind AFB 1 during co-exposures. This hypothesis is further supported by the fact that there were more molecules of fumonisin (3.46 x 10 -5 mole kg ). However, when kinetic excretion data represented in Figs 2 and 3 are reassessed on a molar basis, trends in excretion between single and co-exposures remain consistent.
Apart from the effect of UPSN, the amount of AFM1 and FB 1 excretion in the urine was significantly lower when the toxins were dosed together than when either was dosed alone in the control groups. While it is known that male rats are susceptible to renal damage and potential urinary output changes after repetitive FB 1 exposure (JECFA, 2001), a one-time dose of 25 mg kg -1 body weight is not likely to alter renal function. This conclusion is based upon the fact that male Fischer 344 rats gavaged with up to 23 mg kg -1 body weight for 14 consecutive days exhibited no evidence of renal damage (Gelderblom et al., 1994) . As it is known that AFB 1 is more toxic than FB 1 , the relative reduction in their absorption from the gut should also be considered. In addition, it is known that AFB 1 is absorbed at a high rate, whereas FB 1 is poorly absorbed ranging from 1% to 6% in non-ruminants (Gan et al., 1988; Scholl et al., 1996; Martinez-Larranaga et al., 1999) . Studies utilizing the transepithelial electrical potential suggest that mycotoxins modulate the Na + co-transport involved in sugar and amino acid transport carrier systems (Grenier and Appelgate, 2013) . It is not known whether the uptake of AFB 1 and FB 1 also co-interact via these mechanisms, although the present study implies that they countered each other's absorption from the gut. The modulating role of FB 1 on lipid metabolism with the disruption of sphingolipid, phospholipid, cholesterol, and fatty metabolism has been reported, resulting in toxic effects including an increase in oxidative damage to different cellular constituents including the cellular membrane (Abel and Gelderblom, 1998; Gelderblom et al., 2001; Riley et al., 2001) . These different adverse biological parameters are likely to disrupt membrane integrity, leading to intestinal toxicity (Bouhet and Oswald, 2007) and potentially altered absorption.
Although the urinary biomarkers were reduced when AFB 1 and FB 1 were co-treated, the blood AFB 1 -albumin biomarker was increased in the presence of FB 1 . Multiple pathways of detoxification and activation occur during metabolism of AFB 1 involving many different cytochrome P-450 enzymes (CYP-450). In particular, the AFM1 and AFB 1 -albumin products are considered to be involved in two separate pathways (detoxification and activation, respectively) but can be products of the same enzymes (Massey et al., 1995) . In rats, the formation of AFM1 is catalyzed predominantly by CYP1A1 and 1A2, whereas the production of the AFB 1 8,9-epoxide occurs through catalysis with CYP1A2, CYP2A3, CYP2B7, CYP3A3, and CYP3A4 with the latter isoform having the highest affinity for AFB 1 (Massey et al., 1995) . Higher levels of the AFB 1 -albumin adduct suggest increased production of the most toxic and carcinogenic metabolite, AFB 1 8,9-epoxide in the presence of FB 1 . In earlier work, it was shown that FB 1 induced the activity of CYP1A1, 3A1, and 4A1 in rats after a 6-day intraperitoneal treatment (Martinez-Larranaga et al., 1996) . This induction may be responsible for the higher level of the AFB 1 -albumin adduct observed in this study. Glutathione S-transferases (GSTs) also play a major role in detoxification of the AFB 1 -epoxide in rats, through conjugation with glutathione (GSH). Therefore, a decrease in GST activity and cellular GSH levels could also negatively affect the amount of the AFB-alb biomarker in serum as well. Thus, the carcinogenic potency of AFB 1 is likely to increase in the presence of FB 1 . However, recent work has indicated that FB 1 treatment results in an increase in intracellular GSH levels (Domijan et al., 2011; Rumora et al., 2007) . More studies are warranted to support this conclusion and the consequences of toxin combinations in the diet.
The results from this study provide evidence for an economical and sustainable intervention to reduce exposure to both aflatoxin and fumonisin from contaminated diets. Interesting interactive effects were noticed related to the combined treatment of the mycotoxins in the absence of UPSN, resulting in a 45% and 67% reduction in FB 1 and AFB 1 adsorption. The metabolic conversion of AFB 1 could also be altered resulting in an increased conversion into the 8,9 epoxide and AFM1 presumably owing to the selective induction of CYP isoforms by FB 1 . While more research is warranted to find an optimal inclusion level for UPSN, the prospect of utilizing this clay as a binder for both toxins is promising. This could facilitate important applications to selectively reduce levels below the carcinogenic thresholds for initiation and promotion of hepatocellular carcinoma.
